Aug 5, 2019· Comment from National Community Pharmacists Association (NCPA)· FDA-2019-D-2733-0003
Filed on regulations.gov — full text not in the inline record.
FDANonrulemakingFDA-2019-D-2733
Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency; Immediately in Effect Guidance for Industry; Availability
RIN
—
Last modified
Aug 5, 2019
Comment window
—
National Community Pharmacists Association filings
1
Activity
National Community Pharmacists Association filed 1 comment on this docket between Aug 5, 2019 and Aug 5, 2019. 0 other organizations filed here.
What National Community Pharmacists Association filed (1)
Abstract
No abstract recorded.
View on regulations.gov →Co-filers (0)
See everyone who commented →- National Community Pharmacists AssociationTHIS ORG1 filing · confidence 97%